How to buy TCR2 Therapeutics stock

TCR2 Therapeutics Inc is a biotechnology business based in the US. TCR2 Therapeutics shares (TCRR) are listed on the NASDAQ and all prices are listed in US Dollars. TCR2 Therapeutics employs 118 staff and has a market cap (total outstanding shares value) of 0.00.

TCR2 Therapeutics share price

Use our graph to track the performance of TCRR stocks over time.

TCR2 Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$8.63 - $35.86
50-day moving average	$23.62
200-day moving average	$25.97
Wall St. target price	$45.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-10.67

Buy TCR2 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy TCR2 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of TCR2 Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TCR2 Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-20.71%
Return on equity TTM	-33.82%
Profit margin	0%
Book value	$7.06
Market capitalisation	$884.9 million

TTM: trailing 12 months

Shorting TCR2 Therapeutics shares

There are currently 5.1 million TCR2 Therapeutics shares held short by investors – that's known as TCR2 Therapeutics's "short interest". This figure is 54.4% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting TCR2 Therapeutics shares can be evaluated.

TCR2 Therapeutics's "short interest ratio" (SIR)

TCR2 Therapeutics's "short interest ratio" (SIR) is the quantity of TCR2 Therapeutics shares currently shorted divided by the average quantity of TCR2 Therapeutics shares traded daily (recently around 699097.38651994). TCR2 Therapeutics's SIR currently stands at 7.27. In other words for every 100,000 TCR2 Therapeutics shares traded daily on the market, roughly 7270 shares are currently held short.

However TCR2 Therapeutics's short interest can also be evaluated against the total number of TCR2 Therapeutics shares, or, against the total number of tradable TCR2 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TCR2 Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 TCR2 Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1682% of the tradable shares (for every 100,000 tradable TCR2 Therapeutics shares, roughly 168 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against TCR2 Therapeutics.

Find out more about how you can short TCR2 Therapeutics stock.

TCR2 Therapeutics share dividends

We're not expecting TCR2 Therapeutics to pay a dividend over the next 12 months.

TCR2 Therapeutics share price volatility

Over the last 12 months, TCR2 Therapeutics's shares have ranged in value from as little as $8.6301 up to $35.86. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TCR2 Therapeutics's is 2.0801. This would suggest that TCR2 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

TCR2 Therapeutics overview

TCR2 Therapeutics Inc. , a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016.

Frequently asked questions

• What percentage of TCR2 Therapeutics is owned by insiders or institutions?

  Currently 1.383% of TCR2 Therapeutics shares are held by insiders and 96.755% by institutions.

• How many people work for TCR2 Therapeutics?

  Latest data suggests 118 work at TCR2 Therapeutics.

• When does the fiscal year end for TCR2 Therapeutics?

  TCR2 Therapeutics's fiscal year ends in December.

• Where is TCR2 Therapeutics based?

  TCR2 Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142

• What is TCR2 Therapeutics's ISIN number?

  TCR2 Therapeutics's international securities identification number is: US87808K1060

• What is TCR2 Therapeutics's CUSIP number?

  TCR2 Therapeutics's Committee on Uniform Securities Identification Procedures number is: 87808K106